EUVIMEDEUVIMED entdecken
Crossref

Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall

Maria Danieli iD, Francesco Barretta, Stefano Radaelli, Marco Fiore iD, Claudia Sangalli, Marta Barisella, Elena Palassini, Rosalba Miceli, Anna Maria Frezza iD, Dario Callegaro iD, Paola Collini, Paolo Giovanni Casali und 2 weitere

Cancer · 2023

DOI: 10.1002/cncr.34945 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Maria Danieli und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. Hauptthemen laut MEDLINE: Neoadjuvant Therapy, Fibrosarcoma, Sarcoma. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To explore the correlation between pathological and radiological response to preoperative treatments and outcome in surgically treated patients with myxofibrosarcoma (MFS) and undifferentiated pleomorphic sarcoma (UPS).

Methods

All consecutive patients with primary localized MFS and UPS of the extremities and trunk wall surgically treated with curative intent at our center (2005‐2021) were included. Clinical data including residual visible tumor (VT%) on surgical specimen and Response Evaluation Criteria in Solid Tumor (RECIST) were retrieved. Kaplan–Meier curves for overall survival and disease‐free survival, and cumulative incidence of local relapse and distant metastasis were estimated in a competing risk framework according to RECIST and VT%, overall and by treatment group. Cox and Fine and Gray multivariable models were performed.

Results

Of 693 patients affected by primary MFS and UPS, 233 (66 MFS and 167 UPS) were treated by neoadjuvant chemotherapy (naChT), radiotherapy (naRT), or both (naChT‐RT). VT% was ≤5% in 13/46 (28.2%), 24/99 (24.2%), and 40/88 (45.4%) patients, respectively. There were 11/46 (29.7%), 22/99 (22.7%), and 23/88 (26.1%) RECIST partial responses and 18/46 (48.6%), 59/99 (60.8%), and 60/88 (68.2%) RECIST stable disease, respectively. In naChT, a trend for a better survival was observed when VT% ≤5% ( p = .09), whereas RECIST partial responses and stable disease had the same outcome. VT% was not associated with outcome in naRT or naChT‐RT, whereas RECIST response was.

Conclusion

In primary localized MFS and UPS treated with neoadjuvant therapies, VT% seems more relevant than size reduction after naChT, whereas the opposite is true when naRT is administered alone or concurrent to ChT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoadjuvant TherapyFibrosarcomaSarcomaHumansMaleFemaleMiddle AgedExtremitiesAgedAdultRetrospective StudiesTorsoTreatment OutcomeNeoplasm Recurrence, LocalDisease-Free Survival

Stichwörter der Autor:innen

chemotherapymyxofibrosarcomaradiotherapyresponse, outcomesarcomaundifferentiated pleomorphic sarcoma

Autor:innen und Institutionen

  • Department of Surgery, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

ORCID-Profile: Maria Danieli, Marco Fiore, Anna Maria Frezza, Dario Callegaro, Silvia Stacchiotti

Zitieren

APA

Danieli, M., Barretta, F., Radaelli, S., Fiore, M., Sangalli, C., Barisella, M., Palassini, E., Miceli, R., Frezza, A. M., Callegaro, D., Collini, P., Casali, P. G., Stacchiotti, S., & Gronchi, A. (2023). Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall. Cancer. https://doi.org/10.1002/cncr.34945

Vancouver

Danieli M, Barretta F, Radaelli S, Fiore M, Sangalli C, Barisella M, et al. Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall. Cancer. 2023. doi:10.1002/cncr.34945

BibTeX
@article{Danieli2023,
  author = {Danieli, Maria and Barretta, Francesco and Radaelli, Stefano and Fiore, Marco and Sangalli, Claudia and Barisella, Marta and Palassini, Elena and Miceli, Rosalba and Frezza, Anna Maria and Callegaro, Dario and Collini, Paola and Casali, Paolo Giovanni and Stacchiotti, Silvia and Gronchi, Alessandro},
  title = {Pathological and radiological response following neoadjuvant treatments in primary localized resectable myxofibrosarcoma and undifferentiated pleomorphic sarcoma of the extremities and trunk wall},
  journal = {Cancer},
  year = {2023},
  doi = {10.1002/cncr.34945}
}
Kostenlos starten →